Smoking prevalence in schizophrenia is up to five times higher than other clinical and non-clinical groups ([@bb0030]). Commonalities in the neurobiological substrates of nicotine transmission and the pathology of schizophrenia have led to the proposal that nicotine may be used to 'self-medicate' illness related deficits ([@bb0075]). Schizophrenia is characterised by pathological aberrations in the receptor system responsible for mediating the effects of nicotine ([@bb0080]). Nicotinic cholinergic receptor (nAChR) abnormalities, in turn, have been implicated in the pathogenesis of cognitive dysfunction ([@bb0090]). Of particular interest to the current study, accumulating evidence implicates nAChR dysfunction in the expression of several putative endophenotypic markers of schizophrenia, including sensory gating, sustained attention and spatial working memory ([@bb0100]). Conversely, these domains show "strong evidence" for nicotinic modulation in schizophrenia (see [Table 3](#t0015){ref-type="table"}, [@bb0100]). Specifically, nicotine has been found to transiently ameliorate deficits in auditory sensory gating ([@bb9999]; [@bb0055]), sustained attention ([@bb0035], [@bb0105]) and visual spatial working memory (VSWM; [@bb0105]). Evidence for facilitatory effects of nicotine in non-smokers with schizophrenia ([@bb0005]) and clinically unaffected relatives ([@bb9010]) indicates that these findings are largely independent of withdrawal (and other potential confounds, including chronic exposure to nicotine and psychotropic agents; [@bb9010]). However, there is a paucity of research directly assessing self-reported smoking motivation in schizophrenia ([@bb0045], [@bb0065], [@bb0005], [@bb0050]) and potential cognitive motivators have been largely neglected. Therefore, the degree to which these cognitive effects subjectively motivate smoking remains unclear.

The aims of the current study were three-fold. Firstly, we assessed self-reported smoking motivators, in particular, the perceived importance of cognitive motivators amongst outpatient smokers with schizophrenia and a non-psychiatric comparison group. Secondly, we evaluated the relative impact of smoking abstinence and re-instatement on three tasks measuring putative endophenotypic markers of schizophrenia (sustained attention, visual spatial working memory and sensory gating). Finally, we explored the relationship between self-reported motivations for smoking (i.e. perceived function of smoking) and objective indices of the physiological impact of nicotine on cognitive functioning.

1. Method {#s0005}
=========

This study consisted of two experimental sessions. A 'self-report only' component was also introduced to assess smoking motivation amongst individuals unable or unwilling to participate in experimental sessions. This study was conducted in accordance with the ethical standards (3.10, 8.01, 8.02 and 8.06) of the American Psychological Association. Written, informed consent was obtained from all participants. Study protocol was approved by the University of Newcastle and Hunter New England Human Research Ethics Committees.

1.1. Participants {#s0025}
-----------------

Twenty-eight smokers (≥ 15 cigarettes per day), 16 outpatients who met DSM-IV criteria (DIP; [@bb0015]) for schizophrenia (*n* = 10) or schizoaffective disorder (*n* = 6) and 12 community controls without a personal history of psychosis/major affective disorders (DIP; [@bb0015]) participated in experimental sessions. Exclusion criteria included neurological condition (e.g. stroke, epilepsy), significant head injury/trauma and evidence of alcohol or illicit substance dependence within the last six months. An additional 71 smokers, 43 outpatients with schizophrenia/schizoaffective disorder and 28 non-psychiatric controls provided self-report data only.

1.2. General procedures {#s0030}
-----------------------

Experimental participants attended two morning appointments (approximately one week apart), one after abstaining from nicotine from at least 11 pm (e.g. [@bb9999]; 'abstinent'), the other in the context of usual smoking behaviour ('smoking'). The order of cognitive assessment was randomly allocated from one of six testing orders, generated using a Latin square design. Appointment order (abstinent first vs. second) was alternated within each of the six testing orders. Self-reported smoking motivation was assessed during the 'smoking' appointment. Self-report only participants completed a questionnaire pack assessing demographics, smoking history, self-reported dependence and smoking motivation.

1.3. Measures and instruments {#s0035}
-----------------------------

### 1.3.1. Cigarette and substance use measures {#s0040}

Self-reported smoking status (abstinent vs. smoking) was verified at the beginning of experimental appointments with single breath, expired CO using a Bedfont Micro Smokerlyzer (Air-met Scientific). For the abstinent session a CO reading of ≤ 12 ppm (e.g. [@bb0070]) was required. Withdrawal symptoms were assessed using the Wisconsin Smoking Withdrawal Scale (WSWS; [@bb0130]). Self-reported nicotine dependence was assessed using the Fagerström Test for Nicotine Dependence (FTND; [@bb0120]).

1.4. Smoking motivation {#s0045}
-----------------------

Self-reported smoking motivation was assessed using a revised version of the Modified Reasons for Smoking Scale (MRSS; [@bb0125]). Thirteen items from the Situation × Trait Adaptive Response Smoking Motivation Questionnaire (STAR-SMQ; [@bb0060]) were combined with the MRRS into a single, comprehensive measure of self-reported smoking motivations (MRRS-Revised). Participants were required to rate each item using a five-point Likert scale (1 = Never, 5 = Always; [@bb0045]).

1.5. Cognitive assessment {#s0050}
-------------------------

### 1.5.1. VSWM {#s0055}

VSWM was assessed using a computerized task designed in accordance with published specifications ([@bb0055]). Participants moved a cursor to the location of a previously observed dot with performance indexed by the average distance (error, in cm) between the cursor and the actual location of target presentation, averaged across 16 trials. Higher scores indicate poorer performance.

### 1.5.2. Sustained attention {#s0060}

Sustained attention was assessed using the Continuous Performance Task --- Identical Pairs version (CPT-IP: number trial only; [@bb0095]). Outcome measures included hits (correct responses to targets), false alarms (catch and filler trials), response time (ms) and discrimination \[*d*~L~; [@bb0025]\], calculated for blocks 1 & 2 of the task separately to provide sensitivity to changes over the testing period.

### 1.5.3. PPI {#s0065}

The PPI paradigm was programmed according to published specifications ([@bb0055]). Auditory stimuli were presented binaurally over headphones. Acoustic startle response was measured via eye-blinks using electromyographic activity (EMG) collected using Scan 4.3 (Neuroscan Inc, Biomedics). EMG activity was acquired continuously (A/D rate of 250 Hz) and filtered with a 0.1--30 Hz bandpass filter and 5-Hz notch filter. EMG data were inspected to determine responsiveness of participants to the startle alone stimuli. Participants were classified as 'acoustic startlers' if they demonstrated a mean startle response of ≥ 25 μV in the smoking session ([@bb0055]), with this criterion applied to the mean of the startle alone trial across the first three blocks only (where habituation effects are weakest; [@bb0010]) resulting in the rejection of one schizophrenia participant.

Spontaneous and voluntary eye blinks in these data sets were then excluded according to previously published criteria ([@bb0010]), with 12.5% of trials in controls and 13.89% of trials in schizophrenia participants discarded (comparable to [@bb0055]). Peak amplitude, peak latency and mean amplitude (over 50--200 ms) values were extracted for analysis. PPI was defined as the difference in startle magnitude (as a percentage) between pulse trials preceded by a prepulse and pulse alone trials \[1−(pp/p)×100; where pp represents the mean amplitude to pulse trials preceded by a prepulse, and represents the mean amplitude over pulse alone trials\].

2. Results {#s0010}
==========

Statistical analysis was performed using SPSS v 16.0. An alpha level of .05 was used for all statistical tests.

2.1. Demographic and clinical characteristics {#s0070}
---------------------------------------------

[Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"} display results of independent samples t-tests or X^2^ analyses comparing schizophrenia versus control participants on demographic, clinical and smoking variables. Schizophrenia participants demonstrated lower estimated full scale IQ (although within average limits; [Table 1](#t0005){ref-type="table"}) and higher self-reported nicotine dependence ([Table 2](#t0010){ref-type="table"}).Table 1Demographic and clinical characteristics for experimental (EXP) and self-report participants (S-R)[a](#tf0015){ref-type="table-fn"}.Schizophrenia SmokersControl Smokers*p*-valueEXP\
(*n* = 16)S-R\
(*n* = 43)EXP\
(*n* = 12)S-R\
(*n* = 28)Recruitment Source CTNMH Volunteer Database50%63%----NA ASRB Volunteer Database19%22%----NA HMRI Volunteer Database----25%--NA Media19%--25%7%NA Flyers12%9%50%93%NA Schizophrenia Fellowship--6%----NAAge[b](#tf0020){ref-type="table-fn"}43 (10.8)43 (9.78)37.6 (11.9)37.68 (8.77).025[⁎](#tf0030){ref-type="table-fn"}Gender (% Male)56.348.850.035.7\< .001WTAR Estimated Full-Scale IQ[b](#tf0020){ref-type="table-fn"}99.1 (7.2)104.3 (5.7).05[⁎](#tf0030){ref-type="table-fn"}Self-reported age of illness onset[b](#tf0020){ref-type="table-fn"}21.87 (6.09)19.08 (4.22)NANA.11 Duration21.13 (9.19)24.97 (9.67)NANA.19Antipsychotic class[c](#tf0025){ref-type="table-fn"}NANA-- Atypical1235NANA Typical29NANACPZ equivalents (mg/day)[b](#tf0020){ref-type="table-fn"}363.62 (293.66)612.05 (466.98)NANA.03[⁎](#tf0030){ref-type="table-fn"}[^1][^2][^3][^4][^5]Table 2Smoking variables for experimental and self-report participants[a](#tf0035){ref-type="table-fn"}.Schizophrenia SmokersControl Smokers*p*-valueEXP\
(*n* = 16)S-R\
(*n* = 43)EXP\
(*n* = 12)S-R\
(*n* = 28)Smoking onset (1st full cigarette)12.9 (4.7)13.6 (3.8)14.2 (2.3)13.6 (3.2).77Age of daily smoking onset16.6 (5.3)17 (4.5)16.1 (2.9)16.9 (3.9).53Years since onset of daily smoking26.4 (10.2)25.9 (10.5)21.5 (13.3)20.8 (9.4).13Smoking behaviour in last 12 months[b](#tf0040){ref-type="table-fn"} Abstinent (≥ 1 month)12.517.941.714.3.18 Changed to lower nicotine cigarette18.822.116.728.6.79 Reduced average daily cigarettes31.348.78.353.6.04\* Smoking behaviour unchanged25252532.1.92Lifetime number of quit attempts5.8 (6.8)8.9 (13.6)4 (2)3.8 (4.9).24Longest period of abstinence (weeks)[b](#tf0040){ref-type="table-fn"}.09 \< 112.525027.5 1--42520.82522.5 4--2837.531.358.325 29--522513.5017.5 \> 5209.416.77.5FTND Total Score6.8 (1.8)7.2 (1.7)5.3 (1.6)5.8 (2.1).003[⁎⁎](#tf1005){ref-type="table-fn"}FTND Dependence Category[b](#tf0040){ref-type="table-fn"}.005[⁎⁎](#tf1005){ref-type="table-fn"} Mild2517.65065 High43.841.25020 Very High31.341.2015Duration (min) between cigarettes60.94 (55.92)\
Range = 10--21036.89 (22.36)\
Range = 5--9054.79 (19.3)\
Range = 30--9066.66 (49.02) Range = 15--240.017[⁎](#tf1000){ref-type="table-fn"}[^6][^7][^8][^9][^10]

2.2. Cognitive assessment {#s0075}
-------------------------

Due to small group numbers analysis of all cognitive data was restricted to within-subjects comparisons.

### 2.2.1. VSWM {#s0080}

Paired-samples t-tests demonstrated that schizophrenia \[*t*(15) = 2.93, *p* = .01, Cohen's d = 0.6\], but not control (*p* = .81) smokers demonstrated significantly better performance during typical smoking, relative to short-term (i.e. overnight) abstinence ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1VSWM error demonstrated by schizophrenia and control smokers as a function of smoking status.\*\* p = .01.

### 2.2.2. CPT-IP {#s0085}

Trial block (one vs. two) and smoke status (abstinent vs. smoking) were entered into RMANOVA's performed on each of the CPT-IP performance indices. False alarms to filler trials, catch trials and response time measures were unaffected by smoke status in both groups (all *p*'s \> .17; data not presented).

The proportion of hits, proportion of false alarms and discrimination ability (as a function of smoke status and block) appear in [Fig. 2](#f0010){ref-type="fig"}. An RMANOVA performed on control hits confirmed an interaction between smoke status and block, reflecting decline in performance over blocks \[*F*(1,11) = 11.99, *p* = .005\]. The main effect of smoke status *F*(1,11) = 15.82, *p* = .002\], but not block (*p* = .15) reached significance. Paired samples t-tests confirmed that the proportion of hits significantly declined between blocks one and two in the abstinent \[*t*(11) = 2.80, *p* = .017; Cohen's d = 0.86\] but not smoking appointment (*p* = .19). Conversely, schizophrenia hits appear relatively stable across blocks, irrespective of appointment (confirmed by RMANOVA all *p*'s \> .36).Fig. 2Proportion of hits, proportion of false alarms and discrimination ability (DL) demonstrated by schizophrenia and control smokers as a function of smoking status.\* p = \< .05.\*\* p = \< .01.

In controls, RMANOVA yielded a significant smoke status × block interaction \[*F*(1,11) = 7.89, *p* = .017\] and main effect of smoke status \[*F*(1,11) = 4.82, *p* = .050\]. Discrimination ability significantly improved across blocks in the smoking \[paired *t*(11) = − 2.69, *p* = .021; Cohen's d = 0.8\], but not abstinent appointments (*p* = .27), with sensitivity in block two of 'smoking' significantly higher than block two of 'abstinent' \[*t*(11) = − 3.37, *p* = .006; Cohen's d = 1.09\]. Conversely, the discrimination ability of schizophrenia smokers appears to marginally improve between blocks one and two, irrespective of smoking status. However, RMANOVA's performed on the *d*~L~ data of schizophrenia participants did not reach significance (all *p*'s \> .08).

### 2.2.3. PPI {#s0090}

PPI across the three prepulse intervals (as a function of smoke status) appears in [Fig. 3](#f0015){ref-type="fig"}. RMANOVA's revealed no significant effect of smoke status for either group (all *p*'s \> .19). A significant effect of trial type was detected for control \[ε = 0.71, *F*(2,20) = 19.48, *p* \< .001\], but not schizophrenia participants. In controls, PPI was significantly larger in the 60 ms \[*t*(10) = 5.64, *p* \< .001; Cohen's d = 1.00\] and 120 ms \[*t*(10) = 7.65, *p* \< .001; Cohen's d = 1.09\] conditions relative to the 30 ms condition (no difference was detected between the 60 ms and 120 ms conditions,*p* = .54).Fig. 3Mean percentage prepulse inhibition across trial type for control (A) and schizophrenia (B) smokers as a function of smoke status.

2.3. MRSS-R {#s0095}
-----------

Ninety-eight participants (schizophrenia = 58, control = 40) returned the MRSS-R (one from the schizophrenia group was excluded due to excessive missing data). Mean MRSS-R subscale scores were entered into a 2 (Group: schizophrenia vs. control) × 8 (Motive: cognitive vs. automatic vs. addictive vs. stimulation vs. sedative vs. social vs. indulgent vs. sensorimotor manipulation) RMANOVA, with group as a between-subjects factor and motive as a within-subjects factor. Separate ANCOVA's and Spearman Rank correlations were conducted to determine whether self-reported nicotine dependence (as indexed by FTND scores) influenced self-reported motivation to smoke.

Cognitive motives represent an 'occasional' reason for smoking in both groups ([Fig. 4](#f0020){ref-type="fig"}a). An RMANOVA conducted on the MRSS-R data produced a significant main effect of motive \[ε = .83; *F*(7,672) = 71.09, *p* \< .001\] but no motive × group interaction (*p* = .26) or main effect of group (*p* = .11).Fig. 4Mean MRSS-R subscale scores as a function of clinical group for original (A) and FTND covariate^a^ (B) analysis.Note. FTND = Fagerström Test for Nicotine Dependence (self-report inventory). Responses were scored according to the following scale: 1 = Never, 2 = Seldom, 3 = Occasionally, 4 = Frequently, 5 = Always. ^a^Covariates appearing in the model are evaluated at the following values: FTND = 6.4490.

Cognitive motives continued to represent an 'occasional' reason for smoking in both groups after co-varying for the effect of FTND ([Fig. 4](#f0020){ref-type="fig"}b). FTND was a significant co-variate \[*F*(1,95) = 23.94, *p* \< .001\]. Entering FTND as a covariate in an RMANCOVA produced a significant main effect of motive \[ε = .85; *F*(7,665) = 5.8, *p* \< .001\] along with a significant motive × group interaction \[ε = .85; *F*(7,665) = 2.8, *p* = .01\], with stronger endorsement of sedative motivators amongst controls \[*t*(96) = 3.11, *p* \< .01\]. The main effect of group remained non-significant (*p* = .67). Correlations between FTND and MRSS-R subscale scores are presented at the end of this section in [Table 3](#t0015){ref-type="table"}.Table 3Non-parametric correlations between self reported nicotine dependence (FTND) and MRSS-R subscale scores for schizophrenia and control smokers.SchizophreniaControlFactor*rp*-value*rp*-valueCognitive.230.082.325.041[⁎](#tf0005){ref-type="table-fn"}Automatic.216.103.499.001[⁎⁎](#tf0010){ref-type="table-fn"}Addictive.397.0028.549\< .001[⁎⁎](#tf0010){ref-type="table-fn"}Stimulation.336.010[⁎](#tf0005){ref-type="table-fn"}.309.052Sedative.384.003[⁎⁎](#tf0010){ref-type="table-fn"}.477.002[⁎⁎](#tf0010){ref-type="table-fn"}Social.451\< .001[⁎⁎](#tf0010){ref-type="table-fn"}.122.455Indulgent.171.200− .084.607Sensorimotor Manipulation.171.198− .037.822[^11][^12]

2.4. Relationship between cognitive function and self-reported smoking motivation {#s0100}
---------------------------------------------------------------------------------

Difference scores were calculated for each of the primary cognitive performance indices (Smoking minus Abstinent). Analyses were conducted separately for each group. Significant correlations were detected between self-reported cognitive smoking motivation and CPT-IP measures only and in controls only.

Amongst controls, there was a significant positive correlation between block two hits and the 'cognitive' (*r* = .67, *p* = .02) motivator ([Fig. 5](#f0025){ref-type="fig"}). That is, stronger endorsement of 'cognitive' items was associated with a larger smoking-related increase in block two hit rate.Fig. 5Scattergram^a^ of difference scores for CPT-IP hits (block two) in relation to self-reported 'cognitive' smoking motivation scores in non-psychiatric smokers.^a^Generated from two tailed spearman rank correlate.

3. Discussion {#s0015}
=============

To our knowledge, this is the first study to attempt a multi-level evaluation of subjective and objective cognitive effects of nicotine. Deficits within the three cognitive domains assessed are suspected endophenotypic markers for schizophrenia, and as such, are particularly pertinent to understanding the relationship between nicotine and cognition within this illness. Consistent with prior research ([@bb0105], [@bb0115]), smoking vs abstinence had a clear and significant impact on the VSWM function of smokers with schizophrenia. Relative to overnight abstinence, VSWM performance in the smoking appointment was characterised by significantly smaller error. In contrast, the VSWM performance of control smokers remained consistent across appointments. This study provides further support for the sensitivity of VSWM (dys)function to manipulation of nicotine use in smokers with schizophrenia.

Despite apparent impairments in CPT-IP performance, contrary to prediction, sustained attention in schizophrenia smokers was unaffected by the smoking/abstinence manipulation. Conversely, amongst controls, both hits and discrimination ability were significantly higher in the smoking relative to abstinent appointment. The absence of smoking related change in our schizophrenia group is inconsistent with existing evidence ([@bb0035], [@bb0085], [@bb0105], [@bb0115]). A notable difference between our study and [@bb0035] is the route of nicotine administration (smoking vs. transdermal nicotine patch). Nicotine nasal spray demonstrates a similar pharmacokinetic profile to smoking ([@bb0140]), and consistent with our findings, there is some evidence that CPT-IP performance of smokers with schizophrenia is unaffected by nicotine nasal spray ([@bb0110]). Furthermore, [@bb0085] and [@bb0105] both used Conner's CPT. In Conner's CPT, selective attention and response inhibition are more strongly emphasised ([@bb0035]), whereas CPT-IP (used in the current study) is a more sensitive assessment of sustained attention and working memory processes ([@bb0035], [@bb0095]). One potential implication is that, in schizophrenia, the neural networks mediating selective attention and response inhibition (i.e. Conner's CPT) may demonstrate a differential response to nicotine, relative to sustained attention and working memory (i.e. CPT-IP). Comparing the effect of nicotine across different CPT task versions in a single study may help to clarify apparent discrepancies in the literature.

Contrary to expectation, PPI in smokers with schizophrenia was unaffected by smoking status. In light of existing evidence (e.g. [@bb9999]; [@bb0055]; [@bb2000]; [@bb0135]) it would be premature to interpret the current findings as evidence for an absence of effect. The observed discrepancy between the current findings and existing evidence may result from differences in the proximity between smoking and assessment (due to counterbalancing in the current study) and the use of left, relative to right eye EMG. For example, Cadenhead et al. (2000) demonstrated that, as a group, smokers exhibited higher PPI for right but not left eye EMG ([@bb9956]). The relative effect of nicotine on right vs. left eye EMG represents an interesting area for future research. Utilisation of bilateral recording procedures may help to more clearly elucidate whether smoking related effects in schizophrenia demonstrate evidence of hemispheric asymmetry.

In summary, we predicted that smoking related change on three putative endophenotypic markers would be strongest for smokers with schizophrenia. This hypothesis was supported by evidence from a computerised version of the VSWM task, but not CPT-IP or PPI. Importantly, change in VSWM function was specific to the schizophrenia group and occurred irrespective of the factors that may have contributed to null effects on CPT-IP (e.g. nicotine dose) and PPI (e.g. temporal proximity to nicotine). Evidently, VSWM function may be especially sensitive to smoking related performance change in schizophrenia.

Informed by the cognitive self-medication hypothesis, we predicted that smokers with schizophrenia would offer a higher level endorsement of cognitive motivators for smoking and furthermore, that smokers who reported stronger cognitive motivations for smoking would also demonstrate a stronger impact of nicotine on cognitive functioning. Our data suggest that, on the measures used here, there is no inflation of cognitive motives in schizophrenia relative to non-psychiatric smokers. According to the Primary Addiction Hypothesis ([@bb1000]), addiction is conceived to be a primary symptom of the schizophrenia syndrome, due to fundamental commonalities in the neurobiology of schizophrenia and addiction ([@bb1000]). Therefore, our self-report data could be interpreted as evidence for smoking in schizophrenia as a biologically driven process (addiction vulnerability) that is independent from subjective awareness.

However, we did find an interesting relationship between cognitive motivators and smoking related change in the sustained attention performance of controls. It is noteworthy that the cognitive task with which self-reported cognitive motives did correlate could be argued to be the most general and most easily definable in lay terms --- that is, sustained attention. This finding could be interpreted as having dual implications: that if we wish to assess correlations between motivation and cognition we require tasks that measure general abilities that map well to lay-description of cognitive effects; and that if we wish to better understand the pathways by which nicotine affects cognition, we may require more specific tasks where the contributions of various cognitive operations can be delineated.

The current study is limited by a small sample size, meaning that we were restricted to within subjects comparisons on cognitive measures and correlational analyses were underpowered. Although the reporting of within subjects effects of nicotine versus abstinence in prior research does not enable us to calculate power for PPI and VSWM, the effect size derived from published findings for CPT-IP (Cohen's dz = 0.89; [@bb0035]) supports the expectation for relatively 'large' effects of nicotine (based on [@bb0020]) on this task. For schizophrenia participants, post-hoc power analysis using Gpower (α = .05, two-tailed, dependent means; [@bb0040]) demonstrated adequate statistical power (.80) for detecting moderate to large effects (≥ .75) of nicotine on CPT-IP performance.

If we had not observed any significant effects then one might reasonably question that the significance of the results might be limited by sample size. However, what we did see was a significant effect on VSWM in patients despite no significant effect on CPT-IP and PPI. This result then replicates published findings in an independent laboratory and adds to the evidence that this measure appears particularly sensitive to nicotine effects in schizophrenia. Moreover, unlike several prior investigations (e.g. [@bb0055]; [@bb2000]; [@bb0105]) we did not experimentally manipulate the nicotinic agonist/antagonist administration. It was therefore possible to counterbalance the smoking and abstinent appointment and thereby reduce the contribution of any practice or order effects. This design distinguishes the current study from prior research in the area (e.g. [@bb0085], [@bb0105], [@bb0055]; [@bb9001]) and should be considered in interpreting differences in smoking related effects in the current study, relative to prior research.

It is also worth noting that the abstinent criterion adopted in the current study (\< 12 ppm) is consistent with some (e.g. [@bb1005]; [@bb0070]), but higher than others (e.g. [@bb0105]; [@bb5000]). Given that the mean CO level for both participant groups during the abstinent appointment (control = 8.78; schizophrenia = 8.75) is comparable to studies adopting the more stringent criterion (e.g. [@bb0105]), surreptitious smoking is unlikely to have contributed to our findings. However, future research should consider employing more definitive methods for verifying abstinence (e.g. plasma nicotine levels).

In summary, task choice in this study was based on those for which existing data supported nicotine effects in schizophrenia (see [@bb0100]). Whether these are the most sensitive indices and indeed the specific components of task performance facilitated by nicotine has yet to be determined. Developing sensitive indices of nicotine-induced cognitive enhancement is an important precursor to attempts to link changes in performance on these tasks to self-report motives, as is the challenge of developing more intuitive descriptions of how ability changes might manifest in everyday life. Findings from the current study highlight several methodological considerations for this type of research and promising avenues for future study. Improved understanding of the subjective, neurophysiological and neurocognitive effects of nicotine represents an important step for developing improved smoking cessation strategies.
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[^1]: *Note*. ASRB = Australian Schizophrenia Research Bank; CTNMH = Centre for Translational Neuroscience and Mental Health Research; CPZ = chlorpromazine; HMRI = Hunter Medication Research Institute; WTAR = Weschler Test of Adult Reading.

[^2]: Values are expressed as a percentage of the group unless otherwise specified.

[^3]: Values are expressed as mean (SD).

[^4]: Values are expressed as the total number of participants.

[^5]: Significant at *p* \< .05.

[^6]: *Note*. FTND = Fagerström Test for Nicotine Dependence (self-report inventory).

[^7]: Values are expressed as mean (SD) unless otherwise specified.

[^8]: Values are expressed as a percentage of the group.

[^9]: Significant at *p* \< .05.

[^10]: Significant at *p* \< .01.

[^11]: Significant at *p* \< .05.

[^12]: Significant at *p* \< .01.
